4-O-(2,5-dioxopyrrolidin-1-yl) 1-O-(2-hydroxyethyl) butanedioate | 102743-95-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 4-O-(2,5-dioxopyrrolidin-1-yl) 1-O-(2-hydroxyethyl) butanedioate
• CAS: 102743-95-3
• 化学式: C₁₀H₁₃NO₇
• 分子量: 259.21
• InChiKey: IQUYQRSYQSVSIH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  18
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  110
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• [EN] POLYMERIC CONJUGATES OF ADENINE NUCLEOSIDE ANALOGS<br/>[FR] CONJUGUÉS POLYMÈRES D'ANALOGUES D'ADÉNINE NUCLÉOSIDES
  申请人：ENZON PHARMACEUTICALS INC

  公开号：WO2011130599A1

  公开（公告）日：2011-10-20

  The present invention relates to polymeric conjugates of adenine nucleoside analogs. In particular, the invention relates to multi-arm polyethylene glycol conjugates of adenine nucleoside analogs and use thereof. The present invention, more specifically, provides polymeric conjugates of toyocamycin and its derivatives. Furthermore, the present invention provides a method for preparing the polymeric conjugates of adenine nucleoside analogs and a method of using the same for for treating a cancer, inhibiting the growth or proliferation of cancer cells, treating a viral infection, treating a disease or condition associated with abnormal expression of VEGF. Most polymeric conjugates of toyocamycin was stable in PBS but released toyocamycin in vivo to provided inhibition of cancer cell growth.

  本发明涉及腺嘌呤核苷类似物的聚合物共轭物。具体而言，本发明涉及腺嘌呤核苷类似物的多臂聚乙二醇共轭物及其使用。更具体地说，本发明提供了豆杆菌素及其衍生物的聚合物共轭物。此外，本发明还提供了制备腺嘌呤核苷类似物的聚合物共轭物的方法，以及使用该方法治疗癌症、抑制癌细胞的生长或增殖、治疗病毒感染、治疗与VEGF异常表达相关的疾病或病况的方法。大多数豆杆菌素的聚合物共轭物在PBS中稳定，但在体内释放豆杆菌素，从而提供了抑制癌细胞生长的作用。
• POLYMERIC CONJUGATES OF ADENINE NUCLEOSIDE ANALOGS
  申请人：Zhao Hong

  公开号：US20130018010A1

  公开（公告）日：2013-01-17

  The present invention relates to polymeric conjugates of adenine nucleoside analogs. In particular, the invention relates to multi-arm polyethylene glycol conjugates of adenine nucleoside analogs and use thereof. The present invention, more specifically, provides polymeric conjugates of toyocamycin and its derivatives. Furthermore, the present invention provides a method for preparing the polymeric conjugates of adenine nucleoside analogs and a method of using the same for treating a cancer, inhibiting the growth or proliferation of cancer cells, treating a viral infection, treating a disease or condition associated with abnormal expression of VEGF. Most polymeric conjugates of toyocamycin was stable in PBS but released toyocamycin in vivo to provided inhibition of cancer cell growth.

  本发明涉及腺嘌呤核苷类似物的聚合物共轭物。具体而言，本发明涉及腺嘌呤核苷类似物的多臂聚乙二醇共轭物及其使用。更具体地说，本发明提供了豆杆霉素及其衍生物的聚合物共轭物。此外，本发明提供了一种制备腺嘌呤核苷类似物的聚合物共轭物的方法以及使用该方法治疗癌症、抑制癌细胞生长或增殖、治疗病毒感染、治疗与VEGF异常表达相关的疾病或病况的方法。大多数豆杆霉素的聚合物共轭物在PBS中稳定，但在体内释放豆杆霉素以提供抑制癌细胞生长的作用。
• Oxygen carrier
  申请人：AJINOMOTO CO., INC.

  公开号：EP0067029A2

  公开（公告）日：1982-12-15

  A modified haemoglobin for use as an oxygen carrier in a blood substitute is prepared by covalently bonding haemoglobin or a haemoglobin derivative to a polyalkylene glycol, via an amide bond. A carboxyl group is first introduced onto the polyalkylene glycol, and is then reacted with an amino group of the haemoglobin or haemoglobin derivative to form the amide bond.

  通过酰胺键将血红蛋白或血红蛋白衍生物与聚亚烷基二醇共价键合，可制备用作血液替代品中氧载体的改性血红蛋白。首先在聚亚烷基二醇上引入一个羧基，然后与血红蛋白或血红蛋白衍生物的氨基反应形成酰胺键。
• Hirudin peptides for inhibiting platelet aggregation
  申请人：BIOGEN, INC.

  公开号：EP0372670A2

  公开（公告）日：1990-06-13

  This invention relates to anticoagulant and platelet inhibitory compositions, combinations and methods characterized by biologically active peptides which display the anticoagulant and platelet inhibitory activities of hirudin, or analogs thereof, for therapeutic and prophylactic purposes. The methods, compositions and combinations of this inven­tion are advantageously useful for decreasing or preventing platelet aggregation and platelet activa­tion in a patient or a biological sample. These methods, compositions and combinations are particu­larly useful in patients for whom standard heparin therapy is contraindicated due to a history of heparin-induced thrombocytopenia or an antithrombin III deficiency. This invention also relates to methods, compositions and combinations for treating extracorporeal blood and for increasing platelet storage life.

  本发明涉及用于治疗和预防目的的抗凝剂和血小板抑制剂组合物、组合物和方法，其特征在于生物活性肽具有水蛭素或其类似物的抗凝剂和血小板抑制活性。本发明的方法、组合物和组合物在降低或预防患者或生物样本中的血小板聚集和血小板活化方面具有优势。这些方法、组合物和组合物尤其适用于因肝素诱导的血小板减少症或抗凝血酶 III 缺乏症而禁用标准肝素疗法的患者。本发明还涉及治疗体外血液和延长血小板储存寿命的方法、组合物和组合物。
• Hydrogel compositions
  申请人：SpotLight Technology Partners LLC

  公开号：US10159742B2

  公开（公告）日：2018-12-25

  Fragmented polysaccharide based hydrogel compositions and methods of making and using the same are provided. The subject polysaccharide based hydrogel compositions are prepared by combining a polysaccharide component with a hydrophilic polymer and a cross-linking agent. Also provided are kits and systems for use in preparing the subject compositions.

  本文提供了片段多糖水凝胶组合物及其制造和使用方法。多糖基水凝胶组合物是通过将多糖成分与亲水性聚合物和交联剂结合而制备的。还提供了用于制备上述组合物的试剂盒和系统。